InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
InterCure Ltd.NASDAQ: INCR
Investing Cash Flow · Q2 FY2025 · quarter ended Jun 2025
Investing cash flow turns negative
Q2 FY2025 investing cash flow was -₪2.16M, compared with ₪5.52M a year earlier. Trailing-twelve-month investing cash flow was -₪4.33M. Over 3 fiscal years it compounded at -75.9% a year.
Context
- Investing cash flow amounted to 0.7% of revenue in FY2025, down 6.7 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near -₪2.16M or moves back toward the trailing-twelve-month quarterly average of -₪1.08M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
ILS · from the cash flow
- Latest · FY2025
- (1.99M) ILS
- Year-over-year change
- -111.3%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.99M) | -111.3% |
| FY2024 | 2024-12-31 | 17.69M | +270.6% |
| FY2023 | 2023-12-31 | 4.77M | +103.3% |
| FY2022 | 2022-12-31 | (142.5M) | -118.5% |
| FY2021 | 2021-12-31 | (65.21M) | — |
Investing Cash Flow vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -139.2% is the 8th highest of 9, against a peer median of +138.2%.
- Investing cash flow amounts to 1.8% of revenue for INCR, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.23M USD | +20917.1% | +1721.9% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$12.97M CAD | +935.9% | -46.5% | 70.6% |
| LTM Mar 2026 | $8.96M USD | +164.7% | — | 13.5% | |
| LTM Mar 2026 | $6.06M USD | +111.7% | -34.5% | 5.9% | |
| LTM Mar 2026 | $5.07M USD | -194.9% | — | 2.1% | |
| LTM Jun 2025 | ₪4.33M ILS | -139.2% | -75.9% | 1.8% | |
| LTM Mar 2026 | $550K USD | +268.2% | — | — | |
| LTM Mar 2026 | $243K USD | -72.5% | — | 6.2% | |
| LTM Mar 2026 | CA$60.25K CAD | +102.4% | -31.1% | — | |
| Peer median (excluding INCR) | — | +138.2% | -32.8% | 6.2% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.3M | 43.75M | (63.53M) | (72.79M) | (36.78M) |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| Deferred Income Tax | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Stock-Based Compensation | 6.45M | 8.91M | 2.59M | 2.28M | 2.43M |
| Change in Working Capital | (1.65M) | (3.02M) | (43.55M) | (9.19M) | 18.88M |
| Accounts Receivables | 8.39M | (18.29M) | (23.49M) | 13.26M | 9.29M |
| Inventory | (17.89M) | (75.99M) | 40.21M | (17.44M) | 15.95M |
| Accounts Payables | 2.79M | 57.03M | (47.63M) | (8.9M) | (8.82M) |
| Other Working Capital | 5.06M | 34.22M | (12.63M) | 3.88M | 2.46M |
| Other Non-Cash Items | (5.91M) | (10.16M) | 35.44M | 11.94M | 22.49M |
| Operating Cash Flow | 25.02M | 51.27M | (53.63M) | (66.93M) | 16.84M |
| Capital Expenditures | (14.03M) | (19.74M) | (2.62M) | (4.38M) | (3.55M) |
| Acquisitions (Net) | (19.09M) | (8.32M) | (4.2M) | 405K | 1.67M |
| Purchases of Investments | (1.25M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (30.84M) | (114.44M) | 11.59M | 21.66M | (107K) |
| Investing Cash Flow | (65.21M) | (142.5M) | 4.77M | 17.69M | (1.99M) |
| Debt Repayment | 65.83M | 137.73M | (61.98M) | 7.74M | (29.13M) |
| Common Stock Issued | 128.73M | 0 | 0 | 34M | 1.5M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.38M | (17.28M) | (20.91M) | (15.29M) | (19.03M) |
| Financing Cash Flow | 197.94M | 120.45M | (82.89M) | 26.46M | (46.66M) |
| Effect of Forex Changes | (4.54M) | 7.16M | 297K | (39K) | (44K) |
| Net Change in Cash | 158.33M | 36.37M | (131.45M) | (22.82M) | (31.85M) |
| Free Cash Flow | 10.99M | 31.53M | (56.25M) | (71.3M) | 13.29M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.